WVE Share Price Performance
US$16.56
3.12 (23.21%)
49.2% undervalued intrinsic discount
US$32.60
Fair Value
Price US$16.56
AnalystHighTarget US$32.60
AnalystConsensusTarget US$27.21
AnalystLowTarget US$9.00
Fair ValueUS$32.60
Share Pricen/a
Wave Life Sciences Ltd. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
WVE Community Narratives
AN
Fair Value US$32.6 49.2% undervalued intrinsic discount
Digital Transformation And Precision Medicine Will Drive RNA Therapeutics
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
Fair Value US$27.21 39.1% undervalued intrinsic discount
RNA Readouts And Clinical Milestones Will Broaden Treatment Horizons
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
Fair Value US$9 84.0% overvalued intrinsic discount
Rising Cash Burn Will Hamper RNA Editing Yet Spark Hope
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
RNA Readouts And Clinical Milestones Will Broaden Treatment Horizons
Key Takeaways Positive early clinical data, expanded RNA platform validation, and accelerated trial progress strengthen Wave's position in competitive, growing markets for precision and RNA-based therapies. Strategic partnerships and non-dilutive funds provide financial stability, while increasing market and regulatory acceptance support sustainable growth and profitability.Read more
0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
AN
US$27.21
39.1% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
16.81% p.a.
Profit Margin
20.88%
Future PE
185.2x
Price in 2028
US$32.86
Digital Transformation And Precision Medicine Will Drive RNA Therapeutics
Key Takeaways Innovative RNA platforms and efficient drug development pipeline position the company for rapid adoption, premium pricing, and structural expansion into high-margin, diversified markets. Lead assets demonstrate best-in-class, differentiated mechanisms with wide-ranging potential, threatening incumbents and setting up for significantly larger revenue streams and earnings growth.Read more
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
US$32.6
49.2% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
71.19% p.a.
Profit Margin
15.46%
Future PE
97.16x
Price in 2028
US$39.15
Rising Cash Burn Will Hamper RNA Editing Yet Spark Hope
Key Takeaways Heavy reliance on unproven clinical outcomes and partnership milestone payments exposes the company to liquidity risk and continued net losses if delays or setbacks occur. Intensifying competition, clinical trial risks, and tightening pricing pressures threaten revenue growth, margin improvement, and Wave's ability to sustainably scale in the RNA therapeutics market.Read more
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$9
84.0% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
-25.08% p.a.
Profit Margin
20.92%
Future PE
254.89x
Price in 2028
US$10.8
Trending Discussion
Recently Updated Narratives
AN
WVE: Obesity RNA Editing Breakthrough Is Expected To Drive Future Upside
Fair Value: US$27.21 39.1% undervalued intrinsic discount
8 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Rising Cash Burn Will Hamper RNA Editing Yet Spark Hope
Fair Value: US$9 84.0% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Digital Transformation And Precision Medicine Will Drive RNA Therapeutics
Fair Value: US$32.6 49.2% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Wave Life Sciences Ltd. Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- -0.73
- -59.86%
- -111.64%
- 0%
About WVE
- Founded
- 2012
- Employees
- 288
- CEO
- WebsiteView website
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, an RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-N531, an exon skipping oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
